Industry: Pharmaceuticals, Biotechnology
Bioenvision’s primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra®, Modrenal® (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing anti-infective technologies, including the OLIGON® technology; an advanced biomaterial that has been incorporated into various FDA approved medical devices and Suvus®, an antimicrobial agent currently in clinical development for refractory chronic hepatitis C infection. ( www.bioenvision.com )
Bioenvision , Inc.
345 Park Avenue 41St Floor
New York, New York 10154
USA
Tel: (212) 750-6700
Fax: (212) 750-6777